Factors Contributing to an Accelerated Decline in Pulmonary Function in Asthma  by Kanemitsu, Yoshihiro et al.
Allergology International Vol 63, No2, 2014 www.jsaweb.jp 181
JSA Best Presentation Award 2012
Factors Contributing to an Accelerated
Decline in Pulmonary Function
in Asthma
Yoshihiro Kanemitsu1, Hisako Matsumoto1, Michiaki Mishima1 and
the KiHAC Respiratory Medicine Group
ABSTRACT
Patients with asthma show a steeper age-related decline in pulmonary function than healthy subjects, which is
often alleviated after the initiation of treatment with inhaled corticosteroids (ICS). However, there still are pa-
tients who develop irreversible airflow limitations despite receiving adequate ICS treatment. The identification
of the characteristics of such patients and biomarkers of progression for airflow limitation, a functional conse-
quence of airway remodeling, is considered important in the management of asthma.
A variety of biomarkers are associated with the forced expiratory volume in 1 s (FEV1) in asthma in a cross-
sectional fashion. However, few biomarkers are known to reflect the decline in pulmonary function, particularly
in patients with asthma who receive ICS treatment. Recently periostin, a matricellular protein that prolongs
Th2eosinophilic inflammation and reflects airway remodeling, was reported to be detected in serum. In a Kinki
Hokuriku Airway disease Conference multicenter cohort study, we demonstrated that among several serum
markers, high serum periostin level, particularly95 ngmL, was the only marker associated with a greater an-
nual decline in FEV1 and a decline in FEV1 of30 mL・yr−1. A variant (rs9603226) of the POSTN gene that en-
codes periostin was also involved in the frequency of a decline in FEV1 of30 mL・yr−1.
Our results suggest that the serum periostin level is a useful marker reflecting pulmonary function decline in
patients with asthma receiving ICS.
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INTRODUCTION
Asthma is a chronic inflammatory disorder of the air-
ways characterized by the infiltration of various in-
flammatory cells, cytokines, and mediators, all of
which contribute to the development of airway hyper-
responsiveness (AHR), remodeling,1 and the progres-
sion of airflow limitation,2 a functional consequence
of airway remodeling. As a result of inhaled corti-
costeroids (ICS), the mainstay of asthma treatment,
airway inflammation3 and AHR3 have been well con-
trolled, which then prevents the progression of irre-
versible airflow limitations.4-7 However, some patients
with asthma still develop fixed airflow limitations de-
spite intensive treatment. Indeed, short-term treat-
ment with ICS has been shown to significantly de-
crease airway wall thickening on computed tomogra-
phy,8 whereas long-term treatment with ICS may not
consistently reverse the changes in the remodeled
airways.9 These findings suggest that the response to
long-term treatment with ICS may be heterogeneous
among asthmatic patients, which may relate to insen-
sitivity to ICS. Clarifying the background of asthmat-
ics with progressive airflow limitation would be im-
portant by itself10 and also for providing clues about
ways to overcome insensitivity to ICS treatment.
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Our study group and others have demonstrated a
variety of biomarkers useful in the understanding of
asthma pathogenesis.11-23 Those include markers in
the sputum supernatant,11-19 exhaled air,20,21 and
blood.22,23 However, there have been a limited num-
ber of biomarkers that could be applicable in actual
clinical settings, as mentioned in the recent statement
from the National Institutes of Health.24 The develop-
ment of such clinically applicable biomarkers is thus
warranted for better asthma management.
In this review article, we summarize the factors
that are associated with a decline in pulmonary func-
tion. The effects of ICS treatment are also presented.
We show the role of the serum periostin level as a
biomarker that reflects refractory Th2eosinophilic
inflammation and pulmonary function decline in pa-
tients with asthma who receive ICS.
RISK FACTORS OF PULMONARY FUNC-
TION DECLINE
Pulmonary function reaches a maximum in the early
twenties and starts to decline from around the age
25.25 The earlier studies on the contributing factors
for a decline in pulmonary function demonstrated
that the recent onset of asthma, frequent asthma
symptoms and severe exacerbations, AHR, and smok-
ing history could be risk factors for the decline.
Blood and sputum eosinophilia and genetic predispo-
sition also influenced the accelerated decline in pul-
monary function in patients with asthma (Table 1). In
the following paragraphs, details on these contribut-
ing factors are described. It should be noted, how-
ever, that few of the studies addressed whether stud-
ied patients had been consistently treated with ICS
during the observation periods.
RECENT ONSET OF ASTHMA AND LONG-
STANDING ASTHMA
The recent onset of asthma appears to have a nega-
tive impact on pulmonary function. A 5-year follow-up
survey of the Copenhagen City Heart Study26 and an-
other longitudinal study27 both revealed that adults
who newly developed asthma showed an accelerated
decline in FEV1, whereas those who had already
been diagnosed as having asthma showed a similar
degree of decline in FEV1 to that of nonasthmatic
subjects26,27. A subsequent study showed that pa-
tients with disease duration of <15 years showed a
steeper decline in FEV1 than those with a longer dis-
ease duration.28 In this analysis, baseline FEV1 was
unrelated to disease duration.28
On the other hand, long-standing asthma is also an
important factor for the development of airflow limita-
tion in patients with asthma, particularly in patients
with severe asthma receiving maximal treatment, in-
cluding systemic corticosteroids. The Epidemiology
and Natural History of Asthma: Outcomes and Treat-
ment Regimens study (TENOR study) showed that
60% of people with severe or difficult-to-treat asthma
had persistent airflow limitation as defined by post-
bronchodilator FEV1FVC of 0.7 at two consecutive
annual visits. This study also revealed that longer dis-
ease duration was one of the risk factors that was as-
sociated with persistent airflow limitation.29 Another
cross-sectional study that compared younger patients
and elderly patients with early-onset or late-onset
asthma found that elderly patients who had early-
onset asthma had the most severe airway obstruc-
tion.30 These findings suggest that long-standing
asthma may be also involved in a progressive loss of
pulmonary function.29,30
SEVERITY OF ASTHMA
AHR, one of the hallmarks of asthma, is associated
with not only asthma symptoms, such as wheezing31
and dyspnea,32 but also impaired pulmonary function
growth33 and pulmonary function decline.34,35 In an
18-year follow-up study, Peat et al. demonstrated that
AHR to histamine measured at the end of their study
period was associated with accelerated annual decline
in FEV1 in patients with asthma.34 A subsequent
study revealed that AHR had a marked influence on
the annual decline in FEV1 in atopic patients but not
in nonatopic patients.35 An epidemiological study of a
Dutch cohort revealed that AHR was independently
associated with an accelerated decline in FEV1, irre-
spective of gender, smoking status, age, respiratory
symptoms, and baseline FEV1 levels.36
In addition, persistent symptoms may be a predic-
tive factor for irreversible airflow limitation and accel-
erated pulmonary function decline in patients with se-
vere asthma refractory to corticosteroid therapy.
Among the many symptoms of asthma such as spu-
tum production, cough, wheezing, and dyspnea, an
association has been reported between chronic mu-
cus hypersecretion and an accelerated decline in
FEV1 in nonsmoking patients with asthma.2,26,37
Initial increased airway reversibility to short-acting
β2 agonists and long-term treatment with oral corti-
costeroids were also risk factors for the development
of irreversible airflow obstruction.38 A 10-year follow-
up survey was conducted to evaluate the frequency of
irreversible airway obstruction in life-long nonsmok-
ing adults with long-standing moderate to severe
asthma; the mean age was 37 years, mean disease du-
ration at enrollment was 16 years, and 72% patients
took ICS. At the end of the study, 23% of the studied
patients fulfilled the criteria for irreversible airflow
obstruction and showed a greater decline in FEV1
than patients with reversible airflow obstruction.38
Two recent studies, a historical cohort39 and a pro-
spective cohort,40 showed that severe asthma exacer-
bation may result in an accelerated loss of pulmonary
function. In patients with moderate to severe asthma
who underwent a 11-year follow-up, those who fre-
quently experienced asthma exacerbations (>0.10 ex-
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Allergology International Vol 63, No2, 2014 www.jsaweb.jp 183
Table　1　Risk factors for pulmonary function decline in patients with asthma
Major risk
factors
Authors,
Published year
Follow-up
period
(years)
n
(asthma)
Disease
duration
(years)
Measure-
ments of FEV1 
(per individual)
Specifi c factors associated 
with pulmonary function 
decline in FEV1
Recent 
onset of 
asthma/
long-stand-
ing asthma
Ulrik et al. 199426 5 10952 (396) Data not shown 2 Age at disease onset (>20 
years), Chronic mucus 
secretion
Burrows et al. 199127 13.1 1185 (40) 9.3 7.4 Age at disease onset (>60 
years)
Cibella et al. 200228 5 142 (142) 5.5 (males),
8.8 (females)
10 Disease duration (<15 
years), Reversibility 
(≥15%), Young males
Severity of 
asthma/
symptoms
Peat et al. 198734 18 278 (92) Data not shown 4-7 Airway hyperresponsive-
ness
van Schayck et al. 199135 2 71 (71) Data not shown 6 Airway hyperresponsive-
ness in atopic patients
Lange et al. 19982 15 17506 (1095) Data not shown 3 Chronic mucus secretion, 
Smoking
Postma et al. 199537 13 1439 (231) Data not shown Maximal 8 Chronic mucus secretion, 
Reversibility (≥25%)
Bai et al. 200739 11 93 (93) Data not shown 20.8 Severe exacerbation
O’Byrne et al. 200940 3 315 (315) 0-2 14 Severe exacerbation
Smoking Apostol et al. 200225 10 5057 (613) Data not shown 4 Smoking
James et al. 200543 29 9317 (1301) Data not shown Maximal 7 Smoking
Infl amma-
tion
Broekema et al. 201018 5-14 47 (47) Data not shown 2 Sputum eosinophils, 
Sputum eosinophil cationic 
protein
van Veen et al. 2008†21 5.7 98 (98) 18.5 2 Exhaled nitric oxide
van Rensen et al. 200546 7.5 32 (32) Data not shown 2 Bronchial infi ltrate of CD8 
T lymphocyte
Pasternack et al. 200547 15 245 (83) 15 2 Chronic Chamydophila 
pneumoniae infection in 
nonatopic asthmatics
Kanemitsu et al. 2013†60 8 224 (224) 20.2 16.2 Serum periostin, genetic 
predisposition (POSTN), 
Treatment Step 5, ex-
smoking (≤10 pack-years)
Genetic 
predisposi-
tion
Jongepier et al. 200449 22 152 (152) Data not shown 29 Genetic predisposition 
(ADAM33)
Dijkstra et al. 200650 20.1 129 (129) Data not shown 23 (males)
20 (females)
Genetic predisposition 
(ESR1)
Barton et al. 200951 20.4 2819 (124) Data not shown 22.5 Genetic predisposition 
(PLAUR)
†All participants took ICS treatment.
acerbations・yr−1) showed greater annual decline in
FEV1 than those with infrequent exacerbations.39
Meanwhile, ICS treatment may repress the frequency
of severe exacerbations and the decline in FEV1 in pa-
tients with mild persistent asthma.40
SMOKING
Active smoking worsens not only asthma-related
symptoms41 and airway inflammation14,42 but also ac-
celerates a decline in pulmonary function in patients
with asthma,2,25,43 either in synergistic25 or additive
ways.43 In the Copenhagen City Heart study, smok-
ers who had asthma had a steeper decline in FEV1
than nonsmokers with asthma in a 15-year follow-up.2
Subsequently, the Coronary Artery Risk Develop-
ment In Young Adults study of subjects with the aver-
age age of 24.8 at baseline showed that the initiation
of smoking or exposure to it before age 15 was asso-
ciated with a rapid decline in FEV1 compared with
those participants who never smoked or started
smoking later.25 Furthermore, the combination of
asthma and heavy smoking (15 cigarettes per day)
had a synergic effect on the rate of decline in FEV1.25
In the Busselton Health Survey conducted by James
et al., where the average baseline age of the partici-
pants was 40, showed that asthma and smoking addi-
tively contributed to an accelerated decline in FEV1.43
Lastly, Perret et al. showed a synergic interaction be-
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Table　2　Effects of polymorphisms on an accelerated decline in FEV1 in patients with asthma
Authors,
Published year Gene SNP No. Location Allelic
Risk
genotype
Decline in FEV1 
(mL·yr−1)
Difference compared with 
major homozygous
genotypes (mL·yr−1)
Jongepier et al. 200449 ADAM33 rs528557 3’UTR G/C- CC data not shown -23.7
Dijkstra et al. 200650 ESR1 rs2077647 Exon1 C/T TC -23.1 -11.6
CC -27.2 -15.7
rs9340799 Intron1 G/A AA -27.6 -16.1
rs2234693 Intron1 C/T TT -29.2 -13.3
rs9322331 Intron1 T/C CC -25.8 -15.2
rs4870056 Intron1 A/G GG -28.4 -13.0
Barton et al. 200951 PLAUR rs2356338 5’UTR G/T TT -34.4 -14.6
rs4251953 3’UTR/Intron G/A GA/GG -37.9 -15.9
rs4802189 3’UTR C/A CA/AA -32.4 -13.4
rs4803648 3’UTR T/A AA -36.1 -17.0
TA/AA -31.0 -10.8
Kanemitsu et al. 201360 POSTN rs9603226 Intron21 G/A GA/AA -11.4 -7.3
tween asthma and active smoking on the develop-
ment of fixed airway obstruction (post bronchodilator
FEV1FVC of <0.7),44 which was only observed in
atopic patients with asthma.
INFLAMMATION
Asthma is classically characterized by Th2 and
eosinophilic inflammation. Several cross-sectional
studies showed that sputum eosinophilia and in-
creased eosinophil cationic protein levels were inde-
pendent risk factors for persistent airflow limitation in
patients with severe refractory asthma.16,17 In a longi-
tudinal study of steroid-naïve patients with asthma,
during a mean of 9-year follow-up, Broekema et al.
demonstrated that a greater annual decline in FEV1
was associated with a high number of eosinophil in
the sputum or high eosinophil cationic protein levels,
particularly when patients showed a decline in FEV1
of 30 ml・yr−1.18 Ulrik also proposed the possibility
that higher blood eosinophil counts in childhood
asthma were associated with lower predicted FEV1 in
early adulthood in patients with asthma.45 In patients
with difficult-to-treat asthma, van Veen found that ex-
haled nitric oxide of 20 parts per billion was a pre-
dictor of accelerated decline in FEV1 if their baseline
predicted FEV1 was80%.21
Apart from eosinophils, neutrophils and lympho-
cytes may also be involved in impaired pulmonary
function.19,46 Shaw et al., in a cross-sectional study,
showed that increased sputum neutrophil counts
were associated with lower %FEV1.19 Thereafter, we
found negative correlation between pulmonary func-
tion and the sputum levels of YKL-40 that was mostly
expressed in sputum neutrophils and macrophages.13
In one study with 7.5-year follow-up, CD8+ T lympho-
cytes in bronchial tissue were solely related to an ac-
celerated decline in FEV1.46 In nonatopic patients
with asthma, chronic infection with Chlamydophila
pneumoniae was considered a risk factor for an accel-
erated decline in FEV1.47
GENETIC PREDISPOSITION
The etiology of asthma is complicated because of its
heterogeneity which originates in genetic and envi-
ronmental interaction and variability. Positional clon-
ing, candidate gene screenings, and genome-wide as-
sociation (GWA) studies have identified relationships
between gene variants (single-nucleotide polymor-
phisms; SNPs) and susceptibility to asthma. A recent
GWA study did not identify any SNPs that contrib-
uted to the decline of pulmonary function in adults
with asthma.48 However, earlier candidate gene
screenings that were conducted in a mostly Cauca-
sian population showed associations between pulmo-
nary function decline and several gene variants
[SNPs of A disintegrin and metalloproteinase domain
33 (ADAM33)49, estrogen receptor α (ESR1)50 and
plasminogen activator receptor (PLAUR)51] (Table 1,
2). These associations have been well summarized
elsewhere.52 In a recent cross-sectional study, SNPs
of four genes that are involved in the Th1 or IL-12 cy-
tokine family pathways (IL12A, IL12RB1, STAT4,
and IRF2) were associated with lower percent pre-
dicted FEV1 and disease severity of asthma.53 The
authors proposed a hypothesis of “two-step progres-
sion asthma genetic model,” where genes variants in
the Th2 pathways confer asthma susceptibility and
then variants in the Th1 or IL-12 cytokine family path-
ways affect the impaired pulmonary function.53
THE EFFECT OF ICS ON THE DECLINE IN
PULMONARY FUNCTION
There is increasing evidence that long-term use of
ICS yields beneficial effects on the decline in pulmo-
nary function.4-7 In the Inhaled Steroids Treatment As
Regular Therapy in Early Asthma study, long-term
Contributing Factors of Lung Function
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Fig.　1　Relationship between the serum periostin level and 
the annual decline in FEV1.
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Fig.　2　†Patients who showed a decline in FEV1 of ≥30 
mL·yr−1 were considered rapid decliners.
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treatment with ICS for 3 years decreases the fre-
quency of severe exacerbations,40,54 improves asthma
control,54 and prevents the progression of the decline
in FEV1.4 Meanwhile, several studies have indicated
that the efficacy of ICS may vary according to gen-
der,5 smoking habits,5 or serum total IgE levels.6
Dijkstra et al. demonstrated that only male patients
who had smoked <5 pack-years benefited from inter-
vention with ICS treatment, showing an attenuated
FEV1 decline during a median follow-up of 23 years
(-54.4 mL・yr−1 before ICS intervention vs -17.7 mL・
yr−1 after ICS intervention).5 In the European Com-
munity Respiratory Health Survey study, with a me-
dian follow-up of 9 years, patients with increased se-
rum total IgE levels (>100 kUL) who had been
treated with ICS for 4 years showed less decline in
FEV1 than those who did not receive ICS treatment
(10.7 mL・yr−1 lower decline than ICS nonusers).6
This beneficial effect of ICS was not observed in pa-
tients with lower serum total IgE levels.6
SERUM PERIOSTIN, A PROMISING BIO-
MARKER OF PULMONARY FUNCTION DE-
CLINE
Dozens of biomarkers are associated with FEV1 in a
cross-sectional fashion. However, few biomarkers
that reflect pulmonary function decline have been
identified. Periostin is a matricellular protein, se-
creted from airway epithelial cells55 and lung fibro-
blasts56 in response to IL-4 and IL-13 signaling. It can
bind to other extracellular matrix components such
as collagens I, III, and V, fibronectin, tenascin-C, and
periostin itself.56 Periostin gene expression in airway
epithelial cells of patients with asthma was upregu-
lated compared with that in healthy subjects57 and its
levels correlated with the reticular basement mem-
brane thickness.55 A postmortem study demonstrated
the deposition of periostin on the subepithelial layer
of asthmatic airways.56 Serum periostin was recently
identified as the best biomarker to reflect persistent
airway eosinophilia in patients with severe asthma
who were receiving high-dose ICS (1000 μgday)58
and also predicted the response to anti-IL-13 antibody
treatment.59 Collectively, serum periostin may reflect
Th2eosinophilic inflammation and airway remodel-
ing in asthma.
In a multicenter cohort study of Kinki Hokuriku
Airway disease Conference (KiHAC), we evaluated
the factors associated with an accelerated decline in
pulmonary function in 224 asthmatics receiving ICS
treatment (average age 62.3 years, 171 females).60 In
this study, we assessed the annual changes in FEV1
from at least 1 year after the initiation of ICS treat-
ment to the time of enrollment or later (average, 16.2
measurements over 8 years per individual). Blood
granulocyte counts and several serum markers, in-
cluding serum periostin, high-sensitivity C-reactive
protein, and eosinophil cationic protein were exam-
ined in association with annual decline in FEV1. Se-
rum periostin levels were measured using an
enzyme-linked immunosorbent assay at Shino-test
(Kanagawa, Japan).61 After the adjustment for several
confounding factors, high serum periostin levels, par-
ticularly if they were 95 ngmL, were solely associ-
ated with a greater annual decline in FEV1 (Fig. 1).
This level was determined using the receiver operat-
ing characteristic curve analysis with the highest
specificity (0.985) from a comparison between 224 pa-
tients with asthma (average 92.8 ngmL) and 66
healthy subjects (average 39.1 ngmL). Serum pe-
riostin levels were positively correlated with the pe-
ripheral blood eosinophil counts (r = 0.30, p = 0.0001),
serum eosinophil cationic protein levels (r = 0.25, p =
0.0005), and serum total IgE levels (r = 0.29, p =
0.0001). Other independent risk factors for the de-
cline in FEV1 of 30 mL・yr−1, i.e., the most intensive
treatment step and a history of smoking with light
smoking (10 pack-years) were consistent with previ-
Kanemitsu Y et al.
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ous findings.2,25,43
On univariate analysis, supplemental findings of
the KiHAC cohort study identified risk factors for a
greater decline in FEV1 such as incomplete adher-
ence to medications,62 lower Asthma control testⓇ
scores,63 and comorbidity with or history of sinusi-
tis64 and diabetes mellitus.65 These findings are also
in agreement with previous studies: (1) Shirai et al.
demonstrated weak associations between a low
Asthma control testⓇ score and impaired pulmonary
function (low %FEV1 and %PEF),63 (2) chronic sinusi-
tis, one of the common comorbidities of asthma, is re-
lated to frequent asthma exacerbations66 and decline
in pulmonary function,64 and (3) patients with type 2
diabetes mellitus with poor glycemic control is associ-
ated with the impaired pulmonary function.65
Lastly, a polymorphism of the POSTN gene, which
encodes periostin, was also associated with an accel-
erated decline in pulmonary function in univariate
analysis.60 Patients with the AAAG genotypes of
rs9603226 that is located at intron 21 showed a
higher frequency of a decline in 30 mL than those
with the GG genotype (30% vs 16%) (p = 0.02). In pa-
tients who had high serum periostin levels (95 ng
mL), the frequency of rapid decliners was greater in
patients with of the AAAG genotypes of rs9603226
than in those with the GG genotype (45% vs 19%) (p =
0.01) (Table 2, Fig. 2).
CONCLUSION
Even in patients receiving long-term ICS treatment, a
history of smoking, albeit with a light smoking his-
tory, and the most intensive treatment step remained
characteristics of the rapid decliners, which was in
line with the findings of the earlier studies. Independ-
ent from these clinical characteristics, high serum pe-
riostin, a marker of refractory Th2eosinophilic in-
flammation, was identified as a novel biomarker re-
flecting an accelerated decline in FEV1 in patients
with asthma receiving ICS treatment. Targeting re-
fractory Th2eosinophilic inflammation using serum
periostin might yield better outcomes in asthma man-
agement.
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